Please login to the form below

Not currently logged in


This page shows the latest Vumerity news and features for those working in and with pharma, biotech and healthcare.

Biogen triumphs over Mylan’s Tecfidera patent challenge

Biogen triumphs over Mylan’s Tecfidera patent challenge

Biogen does, however, have its own next-generation MS treatment – Vumerity (diroximel fumarate) – which was recently approved for the treatment of relapsing forms of the disease. ... For comparison, while Tecfidera is a billion-dollar product,

Latest news

More from news
Approximately 2 fully matching, plus 5 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs


Add my company
Hanover Communications

Healthcare is evolving rapidly. To stand out from the crowd requires a potent combination of rich insight, innovative ideas and...

Latest intelligence

01 PME-APR21 Cover.jpg
Virtual congresses: video thrilled the cardio tsar
Chris Ross explores the key learnings from a year of virtual congresses...
When Will We Be Back To Normal?
The definitive question of 2021, whether you’re a homeschooling parent, a homebound professional, a wanderer with nowhere to go… or all three at once....
How to tell your healthcare story.
Healthcare research is not a simple story and the people in charge of those moments need to be careful about the story that they tell....